688046 GemPharmatech
- 12.72
- -0.32-2.45%
GemPharmatech News
Yakkang Biotech (688046): Short-term profit is under pressure, overseas business maintains high growth
Key investment events: On April 27, 2024, the company released the 2023 Annual Report & 2024 First Quarter Report, with 2023 revenue of 622 million yuan (+20.5%, YoY in parentheses, same below)
Yakkang Biotech (688046.SH): A total of 1,522,000 company shares were purchased at a cost of 238.625 million yuan
Gelonghui, April 30, 丨 Yakang Biotech (688046.SH) announced that as of April 30, 2024, the company had repurchased 1,522,000 shares of the company's shares through centralized bidding transactions, accounting for 0.3712% of the company's total share capital of 410,000,000 shares. The highest price of the repurchase transaction was 19.17 yuan/share, the lowest price was 11.89 yuan/share, and the total amount of capital paid was RMB 238.625 million (excluding transaction fees such as stamp duty and transaction fees).
Yakkang Biotech (688046): Overseas market revenue increased 40% year-on-year, and new domestic and foreign production capacity was put into operation one after another
Overseas market revenue increased 40% year over year, and gross margin improved month-on-month. In 2023, the company achieved revenue of 622 million yuan (+20.5% YoY), net profit attributable to mother of 159 million yuan (-3.5% YoY), net profit not attributable to mother
Yakkang Biotech (688046) Company Information Update Report: Production capacity at home and abroad has been put into operation one after another, and international development promotes steady revenue growth
Revenue grew steadily. The profit side was affected by factors such as the release of new production capacity and high-intensity R&D investment. In 2023, the company achieved revenue of 622 million yuan, an increase of 20.45% over the previous year; net profit to mother was 159 million yuan.
Yakkang Biology (688046): Performance is in line with expectations, optimistic about high overseas growth
Investment highlights: Event: The company released its 2023 annual report and 2024 quarterly report, and the performance was in line with expectations. Achieved revenue of 620 million yuan (+20.5%) in 2023, net profit of 160 million yuan (-3.5%) deducted from mother
Yakkang Biotech (688046.SH): Net profit of 294.79 million yuan in the first quarter decreased by 5.06% year-on-year
On April 26, Gelonghui (688046.SH) released its first quarter report. Operating revenue was 157 million yuan, up 11.96% year on year, net profit was 294.79 million yuan, down 5.06% year on year, after deducting non-net profit of 22.868 million yuan, up 2.74% year on year, with basic earnings of 0.07 yuan per share.
Zhitong A Share Sale Restriction and Release List | April 25
According to the Zhitong Finance App, the ban on restricted shares of 3 listed companies was lifted on April 25, with a total market value of about 647 million yuan. Today's specific sales restrictions and unbanned stocks are as follows: Stock abbreviation, stock code, restricted stock type, number of banned shares, Jiechang drives 60,3583 shares incentive sales restrictions and circulation 2375, Wan Rongqi Technology 301,360 shares are restricted in sale and circulation before issuance, 1,244,600, 10,000, Yakang Biotech 68,046 million
Express News | Today, 3 companies lifted the ban on restricted shares, and Rongqi Technology lifted the ban and the market value exceeded 500 million yuan
Yakkang Biotech (688046.SH): The ban on 2 million restricted shares was lifted on April 25
On April 16, Gelonghui (688046.SH) announced that the total number of shares in circulation in the company's current stock listing is 2 million shares. The stock listing and circulation date is April 25, 2024.
Yakkang Biology (688046.SH): No plans to directly enter the field of gene modification therapy
Gelonghui, April 8, 丨 Yakang Biology (688046.SH) said on the investor interactive platform that gene editing technology, as an underlying technology, can be applied in a wide range of fields. The company is closely monitoring technological progress and industry trends. The company is temporarily focusing on the field of model animals and has no plans to directly enter the field of gene modification treatment.
Yakkang Biotech (688046.SH): spent 238.625 million yuan to buy back a total of 1,522,000 shares
Gelonghui, April 2, 丨 Yakang Biotech (688046.SH) announced that as of March 31, 2024, the company had repurchased 1,522,000 shares of the company's shares through centralized bidding transactions, accounting for 0.3712% of the company's total share capital of 410,000,000 shares. The highest price of the repurchase transaction was 19.17 yuan/share, the lowest price was 11.89 yuan/share, and the total amount of capital paid was RMB 238.625 million (excluding transaction fees such as stamp duty and transaction fees).
Investor Optimism Abounds GemPharmatech Co., Ltd. (SHSE:688046) But Growth Is Lacking
With a price-to-earnings (or "P/E") ratio of 40.1x GemPharmatech Co., Ltd. (SHSE:688046) may be sending bearish signals at the moment, given that almost half of all companies in China have P/E ratios
Yakkang Biotech (688046.SH): A total cost of 238.267 million yuan to buy back 0.37% of the shares
Gelonghui, March 1, 丨 Yakang Biotech (688046.SH) announced that as of February 29, 2024, the company had repurchased a total of 1,519,302 shares through the Shanghai Stock Exchange trading system, accounting for 0.3706% of the company's total share capital of 410,000,000 shares. The highest price of the repurchase transaction was 19.17 yuan/share, the lowest price was 11.89 yuan/share, and the total amount of capital paid was RMB 23,826,723.29.
Yakkang Biotech (688046): Performance is in line with expectations, overseas business continues to grow rapidly
Core view: The company released the 2023 annual performance report. In 2023, the company achieved revenue of 622 million yuan (+20.45%, the following are year-on-year values), net profit to mother of 159 million yuan (-3.46%),
Yakkang Biotech (688046): Continued to show business resilience and is optimistic about high overseas growth potential
Investment highlights: Event: The company released its 2023 performance report. The company expects to achieve revenue of 620 million yuan (+20% YoY), net profit to mother of 160 million yuan (-3% YoY) in 2023, after deducting net profit of non-return to mother 1.
The net profit of Yakkang Biotech (688046.SH) in 2023 was 159 million yuan, a year-on-year decrease of 3.46%
According to Zhitong Finance App News, Yakkang Biotech (688046.SH) disclosed the 2023 annual performance report. During the reporting period, the company achieved operating income of 622 million yuan, an increase of 20.45% over the same period last year; net profit attributable to owners of the parent company was 159 million yuan, a decrease of 3.46% over the same period last year. During the reporting period, the company adhered to the concept of “innovative models, unlimited possibilities”, continued to increase investment in R&D, and continued to launch various innovative mouse models in non-tumor fields such as autoimmune diseases, cardiovascular and metabolic diseases, neurodegenerative diseases, etc., to enrich the variety of strains and improve the relevant efficacy evaluation system
Yakkang Biology (688046): Dawn gradually appeared and set sail at sea
Revenue and profit growth improvement The company released the 2023 performance report on February 23: Achieving operating income/net profit to mother/net profit after deducting non-net profit of $6.22/1.59/107 million yuan in 2023 (+20/-3
GemPharmatech Co., Ltd. (SHSE:688046) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
GemPharmatech (SHSE:688046) has had a rough month with its share price down 37%. But if you pay close attention, you might find that its key financial indicators look quite decent, which could mean
Yakkang Biology (688046): Model animal leaders go overseas to open a second growth curve
The company's performance continues to grow rapidly. Yakkang Biotech was founded in 2017. It has a certain historical heritage relationship with Nanjing University and the Institute of Biology it manages in terms of personnel and assets. Its main business is to sell commercialized products with independent intellectual property rights
Yakkang Biotech (688046.SH): A total of 1.003 million shares have been repurchased as of January 30
Gelonghui, January 30, 丨 Yakang Biotech (688046.SH) announced that as of January 30, 2024, 1,030,000 shares of the company had been repurchased through centralized bidding transactions through the Shanghai Stock Exchange trading system, accounting for 0.2446% of the company's total share capital. The highest price of the repurchase transaction was 19.17 yuan/share, the lowest price was 13.38 yuan/share, and the total amount of capital paid was RMB 17,075,570.41 (excluding transaction fees such as stamp duty and transaction fees).
Analysis
Price Target
No Data
